News

Biomay Appoints Rainer Henning as Chief Executive Officer (20 Jan. 2011)

Biomay announces the appointment of Dr. Rainer Henning as new Chief Executive Officer. Rainer Henning looks back at a 30-year career in the pharmaceutical and biotechnology industry and in venture capital investing. From 2005 to 2010, he was CEO of Fibrex Medical, Inc., a Cambridge based biopharmaceutical company developing peptides for acute care indications, including myocardial infarction, acute lung injury and transplantation. After a successful clinical PoC study, he was responsible for partnering the Fibrex portfolio with Ikaria Holdings in the US.

From 2000 to 2004, Rainer Henning served at Future Capital and Brilleon Capital as investment manager and partner. Holding a PhD in chemistry, he began his career at Hoechst AG (now part of Sanofi Aventis) where he held multiple operational and senior management positions, including Deputy Head of Cardiovascular Research and Managing Director of the Japanese Subsidiary, Nippon Hoechst Marion Roussel. He is co-inventor of Tritace® and Odrik®, two blockbuster antihypertensives, and author of >80 granted patents.

“I am extremely excited to join the experienced team at Biomay”, commented Rainer Henning. “The company has the most advanced technology worldwide in the field of specific immunotherapy of allergy. I am committed to bringing our lead product, the innovative grass pollen vaccine BM32, to clinical success for the benefit of the millions of allergy sufferers.”

Max Bayerl, Biomay´s former CEO, stated: “I am very happy that Rainer Henning has agreed to join Biomay, particularly as the company is entering a new and important phase. I am sure that a seasoned pharma manager, such as Rainer is, will make a decisive contribution to the exiting developments lying ahead.”

Max Bayerl has led the company since 2003. During his time Biomay started focussing its research activities, largely executed through its extensive collaboration with leading university based scientists, to create technology platforms for highly innovative allergy vaccines. Four Christian-Doppler Laboratories, dedicated to allergy research, were established in this process. Another significant achievement was the setting up of a GMP facility.

Biomay thanks Max Bayerl for his contributions and wishes him all the best for the future.

go back to news archive